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Purpose: The aim of this research was to examine the molecular and clinical features that are 
related with EGFR-tyrosine kinase inhibitor (EGFR-TKI) efficacy in previously treated patients 
with squamous cell carcinoma of the lung (SCCL).
Materials and methods: This retrospective study included 67 SCCL patients with obtainable 
lung cancer tissue and records on EGFR-TKI treatment response and survival. EGFR protein 
expression in lung cancer tissue was measured by immunohistochemistry with a specific antibody 
that recognizes the intracellular domain (ID) of EGFR. PTEN expression in lung cancer tissue 
was also evaluated with immunohistochemistry. PI3KCA gene amplification was detected by 
quantitative real-time polymerase chain reaction, and FGFR1 amplification was assessed by 
fluorescent in situ hybridization.
Results: EGFR ID expression (hazard ratio [HR] 0.53, P=0.022) and Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) (HR 0.43, P=0.022) were significantly related 
with progression-free survival following EGFR-TKIs treatment. PTEN expression (HR 0.52, 
P=0.025) was significantly related to overall survival. The group of EGFR-positive or PTEN-
positive patients with ECOG PS of 0 or 1 had better clinical outcomes than patients who were 
EGFR-negative and PTEN-negative or who had poor ECOG PS with longer median progression-
free survival (2.1 vs 1.0 months, P=0.05) and overall survival (6.2 vs 2.1 months, P=0.05).
Conclusion: EGFR expression using an ID-specific antibody and PTEN protein expression 
may be used to identify SCCL patients who might benefit from EGFR-TKI treatment.
Keywords: EGFR, tyrosine kinase inhibitor, squamous cell carcinoma, lung, intracellular 
domain, PTEN
Introduction
EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are responsible for significant clinical 
improvement in the treatment of non-small-cell lung carcinoma (NSCLC) patients, 
specifically NSCLC patients with an activating EGFR mutation. Prospective Phase III 
studies on patients with advanced lung adenocarcinoma and EGFR mutations indicated 
that the EGFR-TKI group had meaningfully extended progression-free survival (PFS) 
compared with the platinum-based doublets treatment cohort.1 Other clinical trials have 
reported that patients with wild-type EGFR also benefit from EGFR-TKI therapy as a 
second- or third-line treatment.2,3 A previous study by Lee et al showed that high EGFR 
gene copy number and skin rash were associated with EGFR-TKI sensitivity and longer 
PFS in patients with squamous cell carcinoma of the lung (SCCL).4 Chang et al proposed 
correspondence: Jong-seok lee
Division of hematology and Medical 
Oncology, Department of internal 
Medicine, seoul national University 
Bundang hospital, seongnam 463-707, 
gyeonggi, republic of Korea
Tel +82 31 787 7039
Fax +82 31 787 4098
email jslee@snubh.org 
Journal name: OncoTargets and Therapy
Article Designation: Original Research
Year: 2016
Volume: 9
Running head verso: Chang et al
Running head recto: EGFR and PTEN in squamous cell carcinoma of lung
DOI: http://dx.doi.org/10.2147/OTT.S107291
OncoTargets and Therapy 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5154
chang et al
that MET protein expression in lung cancer tissue might be 
a biomarker to predict benefit from EGFR-TKIs for NSCLC 
patients, irrespective of EGFR mutation status.5 The identifi-
cation of additional molecular markers predictive of clinical 
benefit from EGFR-TKIs in EGFR wild-type tumors would 
have important implications for NSCLC patients.5
The aim of this study was to examine the molecular and 
clinical factors associated with EGFR-TKI efficacy in previ-
ously treated patients with SCCL, in whom the prevalence 
of activating EGFR mutations is 5%.4 We particularly 
concentrated on expression of EGFR and PTEN proteins, 
and amplification of PI3KCA and FGFR1 genes.
Materials and methods
Patient selection
This retrospective study included 85 consecutive SCCL 
patients who received gefitinib (Iressa®, 250 mg/d) or 
erlotinib (Tarceva®, 150 mg/d) for metastatic SCCL at Seoul 
National University Bundang Hospital (SNUBH; Seongnam, 
Korea) from January 2005 to December 2011. Tumor sam-
ples from 67 patients were available for analysis. All of the 
tissues were obtained at the time of the primary diagnosis 
by biopsy (n=61) or surgical resection (n=6). The medical 
charts and radiographic images of the patients were then 
reviewed to assess their clinicopathological characteristics, 
tumor responses, and survival outcomes using a predesigned 
data collection format. This study was approved by the 
Institutional Review Board of SNUBH and written informed 
consent was obtained from each patient.
egFr ihc staining and analysis of egFr 
mutation status
EGFR protein expression in lung cancer tissue was measured 
by immunohistochemistry (IHC) with a specific antibody 
(5B7) that identifies the intracellular domain (ID) of EGFR 
(#790-4347; Ventana Medical Systems, Inc., Oro Valley, 
AZ, USA).
This domain is directed against the epitope located at the 
SOCS3 protein-binding site and also detects truncated forms 
of the receptor that are constitutively active.6
IHC scoring was carried out by two pathologists accord-
ing to H-scoring criteria. The H-score is derived by summing 
the percentage of positive cells (0%–100%) and the intensity 
(0–3) for that group, resulting in a final IHC score ranging 
from 0 to 300. We defined positive EGFR expression as an 
H-score 100.
A mutation analysis was carried out in the 66 patients 
(98.5%) for whom adequate tissue was available. 
Paraffin-embedded tissue samples consisting of 70% 
tumor cells were used to extract DNA. Mutation analysis 
of EGFR exons 18–21 was carried out using a polymerase 
chain reaction (PCR)-based assay.
PTen ihc staining
PTEN IHC staining was carried out using a rabbit monoclonal 
antibody against PTEN (1:50 dilution, Y184; Epitomics, 
Burlingame, CA, USA). PTEN immunoreactivity was assessed 
based on cytoplasmic staining by using a semiquantitative 
scoring method that divided the samples into four categories 
as follows: 0, negative; 1, 1%–25% positive; 2, 26%–50% 
positive; and 3, 50% positive in tumor cells. A staining 
score of 1 was considered to be positive.7 Analysis of PTEN 
staining was independently performed by two pathologists. In 
the rare instance of a discrepancy in scoring, agreement was 
reached by discussion at a multihead microscope.
copy number analysis of Pi3Kca 
and FgFr
We analyzed the copy number of the PI3KCA gene by 
real-time quantitative PCR with the TaqMan™ Copy 
Number Assays (Hs01353479_cn; Thermo Fisher Scientific, 
Waltham, MA, USA). DNA samples were diluted to a con-
centration of 5 ng/μL. Each PCR mix contained 5.0 μL of 
2X TaqMan Genotyping Master Mix, 0.5 μL of the TaqMan 
Copy Number target assay mix, 0.5 μL of the TaqMan Copy 
Number reference assay (RNase P) mix, which is known 
to exist only in two copies in a diploid genome, 2.0 μL of 
nuclease-free water, and 2.0 μL of DNA, according to the 
manufacturer’s instructions. The reactions were processed 
in an ABI StepOnePlus™ Real-Time PCR System (Thermo 
Fisher Scientific), with each DNA sample analyzed in trip-
licates using cycle conditions of 95°C for 10 minutes for 
one cycle followed by 40 cycles of 92°C for 15 seconds and 
60°C for 1 minute. Data were analyzed using CopyCaller™ 
Software (version 1.0; Thermo Fisher Scientific). A PI3KCA 
gene copy number of 2 was considered to be indicating 
normal human genomic DNA, and a copy number 4 was 
considered to be indicating amplification.
For FGFR1 amplification, a fluorescent in situ hybridiza-
tion (FISH) assay was carried out on the tissue microarrays 
with an FGFR1 probe that hybridizes to the 8p12-8p11.23 
band labeled with Spectrum Orange (red) and a probe to CEN8 
labeled with Spectrum Green (Abbott Molecular, Des Plaines, 
IL, USA), following routine methods. Two experienced 
evaluators who were blinded to the clinical data interpreted 
FISH data. At least 100 nuclei per patient were evaluated. 
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A positive FGFR1 result (ie, amplification) was defined as 
one of the following conditions:8
1. FGFR1/CEN8 ratio 2.0;
2. average number of FGFR1 signals per tumor cell 
nucleus 6;
3. percentage of tumor cells containing 15 FGFR1 signals 
or large clusters 10%; and
4. percentage of tumor cells containing 5 FGFR1 sig-
nals 50%.
assessment
Tumor response was assessed by a computed tomography 
scan, which was typically performed every 8 weeks, in 
accordance with the guidelines established by the Response 
Evaluation Criteria in Solid Tumors.
statistical analysis
For comparisons of patient groups, Fisher’s exact or χ2 test 
was used as appropriate. A P-value 0.05 was considered 
statistically significant (two-tailed). PFS was computed 
from the start of EGFR-TKIs treatment until progression 
or death, and overall survival (OS) was calculated from 
the start of TKIs treatment until death from any cause. The 
Kaplan–Meier method was used to create survival curves, 
and differences between groups were examined with the log-
rank test. Cox regression analysis was used for multivariate 
analysis with a significance level of 0.05. Factors significant 
at the P0.1 level in univariate analyses were entered into 
the Cox proportional hazards model. All statistical analyses 
were performed with SPSS software version 14.0 (SPSS Inc., 
Chicago, IL, USA).
Results
Patient characteristics
The median patient age was 70 years (range: 41–89 years); 
85% were male, and 82% were ever smokers. Patients 
had received a median of 2 prior chemotherapy regimens 
(range: 1–4 regimens) for advanced lung cancer before 
treatment with gefitinib or erlotinib. Eighty-four percent 
(n=56) of the patients were treated with erlotinib, and the 
rest (n=11) received gefitinib. Survival data were col-
lected until December 2014, and the median follow-up 
duration was 33.6 months (95% confidence interval [CI]: 
5.8–61.4 months).
Molecular testing
Molecular panel testing was conducted for EGFR protein 
expression, EGFR mutation, PTEN protein expression, 
PI3KCA amplification, and FGFR1 amplification (Figures S1 
and S2). EGFR IHC and EGFR mutation analyses were suc-
cessfully performed on 66 (99%) and 66 (99%) participants, 
respectively. The median H-score for EGFR expression 
with ID-specific antibody was 320 (range: 0–400). EGFR 
positivity was detected in 56 (85%) cases. There was no case 
of activating EGFR mutation. IHC for PTEN was performed 
in 66 (99%) cases, 41 of which showed a positive result 
(78%). The median PTEN staining score was 2 (range: 0–3). 
Analysis of PI3KCA amplification was performed in 65 (97%) 
cases, which showed an 18% incidence (12/67). The median 
PI3KCA gene copy number was 3 (range: 1–15 copies). 
Fifty-four samples (81%) were available for FGFR1 FISH 
analysis, seven of which showed amplification of FGFR1 
(13%). The prevalence of EGFR positivity, PI3KCA ampli-
fication, and FGFR1 amplification did not differ according 
to age, sex, smoking status, Eastern Cooperative Oncology 
Group (ECOG) performance status (PS), or number of pre-
vious chemotherapy regimens. However, PTEN-positive 
patients were significantly more likely to be female and never 
smokers (Table 1). The smoking dosage of PTEN-positive 
patients (30 pack-years) was statistically lower than that of 
the PTEN-negative group (45 pack-years, P=0.028). Other 
calculated clinicopathological features were not related to 
PTEN expression.
Tumor response
Of the 55 patients available for response evaluation, two 
(4%) had a partial response, 26 (47%) had stable disease, 
and 27 (49%) had progressive disease as their best tumor 
response. Therefore, the objective response rate was 4%, and 
the disease control rate was 51%. There was no difference 
in objective response rate or disease control rate according 
to clinical or biomarker characteristics.
survival outcome
For the total patient population, the median PFS and OS were 
1.8 (95% CI: 1.4–2.1) and 5.5 months (95% CI: 3.6–7.3), 
respectively.
Analysis of PFS showed that EGFR ID expression and 
ECOG PS were significantly associated with PFS follow-
ing EGFR-TKIs treatment (Figure 1). Multivariate analysis 
showed that EGFR ID expression and ECOG PS were inde-
pendent factors for PFS, and EGFR ID expression was an 
independent factor for improved PFS (hazard ratio [HR] 0.53, 
95% CI: 0.31–0.91, P=0.022) (Table 2). Patients with good 
PS of 0 or 1 were at lower risk of progression than those with 
poor PS (HR 0.43, 95% CI: 0.21–0.88, P=0.022) (Table 2).
OncoTargets and Therapy 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5156
chang et al
T
ab
le
 1
 c
or
re
la
tio
ns
 b
et
w
ee
n 
de
m
og
ra
ph
ic
 c
ha
ra
ct
er
is
tic
s 
an
d 
m
ol
ec
ul
ar
 s
ta
tu
s
P
at
ie
nt
  
ch
ar
ac
te
ri
st
ic
s
N
o
%
E
G
FR
 IH
C
 +
 (
n=
56
)
P-
va
lu
e
P
T
E
N
 IH
C
 +
 (
n=
41
)
P-
va
lu
e
P
I3
K
C
A
 a
m
p 
+ 
(n
=1
2)
P-
va
lu
e
FG
FR
 a
m
p 
+ 
(n
=7
)
P-
va
lu
e
N
o/
su
bg
ro
up
 (
%
)
N
o/
su
bg
ro
up
 (
%
)
N
o/
su
bg
ro
up
 (
%
)
N
o/
su
bg
ro
up
 (
%
)
T
ot
al
67
10
0
Se
x
1.
0
0.
01
*
1.
0
0.
57
M
al
e
57
85
.1
47
/5
6
31
/5
6
11
/5
2
7/
46
Fe
m
al
e
10
14
.9
9/
10
10
/1
0
1/
7
0/
8
A
ge
 (
ye
ar
s)
1.
0
0.
79
0.
73
0.
08

65
23
34
.3
20
/2
3
15
/2
3
3/
20
0/
18

65
44
65
.7
36
/4
3
26
/4
3
9/
39
7/
36
E
C
O
G
 P
er
fo
rm
an
ce
0.
49
1.
0
0.
51
1.
0
0,
 1
41
61
.2
35
/4
0
25
/4
0
9/
37
4/
31

2
26
38
.8
21
/2
6
16
/2
6
3/
22
3/
23
Sm
ok
in
g
1.
0
0.
02
3*
0.
66
0.
58
n
ev
er
12
17
.9
10
/1
2
11
/1
2
2/
8
0/
9
ev
er
55
82
.1
46
/5
4
30
/5
4
10
/5
1
7/
45
P
re
vi
ou
s 
ch
em
ot
he
ra
py
 
tr
ea
tm
en
ts
1.
0
0.
78
0.
48
0.
40

2
46
68
.7
38
/4
5
27
/4
5
7/
41
6/
36

3
21
31
.3
18
/2
1
14
/2
1
5/
18
1/
18
E
G
FR
-T
K
I
0.
67
0.
18
0.
18
1.
0
G
efi
tin
ib
11
16
.4
9/
11
9/
11
0/
9
1/
9
er
lo
tin
ib
56
83
.6
47
/5
5
32
/5
5
12
/5
0
6/
45
T
is
su
e 
sp
ec
im
en
0.
56
0.
39
0.
59
1.
0
r
es
ec
tio
n
6
91
.0
6/
6
5/
6
2/
6
0/
1
Bi
op
sy
61
9.
0
50
/6
0
36
/6
0
10
/5
3
7/
53
N
ot
e:
 *
P
0.
05
.
A
bb
re
vi
at
io
ns
: a
m
p,
 g
en
e 
am
pl
ifi
ca
tio
n;
 IH
C
, i
m
m
un
oh
is
to
ch
em
is
tr
y;
 T
K
I, 
ty
ro
si
ne
 k
in
as
e 
in
hi
bi
to
r.
OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5157
egFr and PTen in squamous cell carcinoma of lung
Analysis of OS revealed that PTEN expression and ECOG 
PS were significantly related to OS (Figure 2). In the multivari-
ate analysis of OS, patients with PTEN expression were at a 
lower risk of death than PTEN-negative patients (HR 0.52, 95% 
CI: 0.30–0.93, P=0.025) (Table 2). ECOS PS of 0 or 1 showed 
borderline statistical significance (HR 0.59, 95% CI: 0.35–1.0, 
P=0.053) (Table 2). Neither PI3KCA amplification nor FGFR1 
amplification was related with PFS or OS.
combined egFr iD/PTen expression 
and ecOg Ps
Treatment results for the subgroups were categorized accord-
ing to the combined criteria of EGFR ID/PTEN expression 
and ECOG PS. The group of EGFR-positive or PTEN-positive 
patients with ECOG PS of 0 or 1 had better clinical outcomes 
than the groups who were EGFR- and PTEN-negative or who 
had poor ECOG PS with longer median PFS (2.1 [95% CI: 
1.6–2.6] vs 1.0 month [95% CI: 0.4–1.6], respectively; P=0.05) 
and longer median OS (6.2 [95% CI: 4.8–7.5] vs 2.1 months 
[95% CI: 0.5–3.7], respectively; P=0.05) (Figures 1 and 2).
Discussion
We investigated molecular markers of clinical outcome for 
EGFR-TKI treatments in SCCL patients. To the best of our 
knowledge, this study is the first to show a strong associa-
tion of EGFR ID and PTEN expressions with PFS and OS in 
EGFR wild-type SCCL treated with EGFR-TKI.
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Figure 1 Progression-free survival curves of the two groups according to ecOg Ps, egFr iD and PTen.
Notes: (A) ecOg Ps, (B) egFr iD expression, and (C) the combined criteria of ecOg Ps, egFr iD expression, and PTen expression in patients with advanced squamous 
cell lung cancer who were receiving gefitinib or erlotinib as second-line or higher therapy.
Abbreviations: ecOg, eastern cooperative Oncology group; iD, intracellular domain; PFs, progression-free survival; Ps, performance status.
Table 2 Multivariable analysis of progression-free and overall 
survival
Variable PFS OS
HR 95% CI P-value HR 95% CI P-value
EGFR ID
negative 1 –
Positive 0.53 0.31–0.91 0.022* –
PTEN
negative – 1
Positive – 0.52 0.30–0.93 0.025*
ECOG
0, 1 0.43 0.21–0.88 0.59 0.35–1.0
2 1 0.022* 1 0.053
Note: *P0.05.
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology 
group; hr, hazard ratio; iD, intracellular domain; Os, overall survival; PFs, 
progression-free survival.
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EGFR external domain protein expression is not recom-
mended as a marker for predicting outcomes of treatment 
with EGFR-TKIs because of debatable clinical results. 
Some studies have indicated superior outcomes after EGFR-
TKI treatment for lung cancer overexpressing the EGFR 
protein,9,10 whereas other studies have not.11 The discordant 
results of these studies may be due to inadequate sensitivity 
of these methods, lack of strictness in the evaluation, cohort 
differences, or confounding factors due to the concomitant 
administration of chemotherapy.11 EGFR protein expression 
using the ID-specific 5B7 antibody could predict response 
to gefitinib and increased PFS/OS from gefitinib in NSCLC 
patients.6 The antibody detects the SOCS3-binding epitope 
of the ID. Binding of SOCS3 to EGFR is assumed to inhibit 
the EGFR signaling pathway.12 Consequently, when SOCS3 
is present, EGFR is inactive, and the 5B7 antibody cannot 
bind because of steric hindrance. The 5B7 antibody can only 
bind the receptor on this particular epitope, when SOCS3 
is not present and cannot inhibit the EGFR pathway. This 
may explain the improved ability of 5B7-mediated detection 
&
/RJUDQNWHVW3 
3UR
EDE
LOLW\
RI2
6
0RQWKV        






36RU(*)5±DQG37(1±Q 
36DQG(*)5RU37(1Q  

0HGLDQ26

$ %


/RJUDQNWHVW3  /RJUDQNWHVW3 


      0RQWKV
3UR
EDE
LOLW\
RI2
6
3UR
EDE
LOLW\
RI2
6
0RQWKV           






36Q 36Q  
0HGLDQ26 37(1Q 37(1±Q  
0HGLDQ26
Figure 2 Overall survival curves of the two groups according to ecOg Ps, PTen and egFr iD.
Notes: (A) ecOg Ps, (B) PTen expression, and (C) the combined criteria of ecOg Ps, egFr iD expression, and PTen expression in patients with advanced squamous 
cell lung cancer who were receiving gefitinib or erlotinib as second-line or higher therapy.
Abbreviations: ecOg, eastern cooperative Oncology group; iD, intracellular domain; Os, overall survival; Ps, performance status.
of EGFR to predict the clinical benefit of EGFR-TKIs.6 
In addition, 5B7 antibody is able to detect EGFR with trunca-
tion of the external domain, which was found in 5%–8% of 
SCCL.13 As the truncated-form of external domain is consti-
tutively activated, use of an ID-specific antibody might better 
predict response to EGFR-TKIs than anti-EGFR antibody 
that detects the external domain. This hypothesis should be 
validated by further experimentation.
PTEN is a phosphatase that has a tumor suppressor func-
tion. Loss of PTEN activity leads to hyperactivation of the 
PIK3-AKT pathway. PTEN loss can occur at the genomic 
level or as an alternative mechanism as promoter hypermethy-
lation, alternative splicing of pre-mRNA, and posttranslational 
modifications. The overall rate of PTEN inactivation is more 
frequent than that identified at the genomic level; for example, 
promoter methylation is found in 35% of PTEN-negative 
NSCLC.14 PTEN mutations are described in 10% of SCCL 
samples, compared with 2% of adenocarcinoma.15 The close 
relationship between the loss of PTEN expression and the poor 
clinical outcomes of NSCLC has been previously reported.16,17 
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In conclusion, EGFR protein expression using an 
ID-specific antibody and PTEN protein expression may be 
used to identify SCCL patients who are likely to benefit from 
EGFR-TKI treatment. However, due to the limitations of 
retrospective, single-institution studies with relatively small 
numbers of patients, future prospective clinical studies should 
be planned to validate our findings.
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Figure S1 representative immunohistochemistry for (A) egFriD and (B) PTen.
Note: Digital pictures were taken at ×200 and ×1,000 (insert) magnification: positive (left) and negative (right).
Abbreviation: iD, intracellular domain.
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Figure S2 FgFr1/cen8 Fish signal patterns.
Notes: Different distribution patterns of FgFr1 (green) and cen8 signals (orange) were seen in squamous cell carcinomas. (A) Homogeneously non-amplified tumor with 
one to two FgFr1 signals on average. (B) Isolated tumor cell nucleus with high-level cluster amplifications of FGFR1 signals. (C) The average number of FgFr1 signals per 
tumor cell nucleus is 6. (D) The percentage of tumor cells containing large cluster is 10%.
Abbreviation: FISH, fluorescent in situ hybridization.
